| 2859 - 2861 |
Introduction to Cancer Chemotherapeutics
Shewach DS, Kuchta RD |
| 2862 - 2879 |
Mechanisms of DNA Polymerases
Berdis AJ |
| 2880 - 2893 |
Enzymology of Purine and Pyrimidine Antimetabolites Used in the Treatment of Cancer
Parker WB |
| 2894 - 2902 |
DNA Topoisomerase I Inhibitors: Chemistry, Biology, and Interfacial Inhibition
Pommier Y |
| 2903 - 2928 |
IMP Dehydrogenase: Structure, Mechanism, and Inhibition
Hedstrom L |
| 2929 - 2950 |
Targeting the DNA Damage Response in Cancer
Ljungman M |
| 2951 - 2973 |
DNA Structure and Integrity Checkpoints during the Cell Cycle and Their Role in Drug Targeting and Sensitivity of Tumor Cells to Anticancer Treatment
Skladanowski A, Bozko P, Sabisz M |
| 2974 - 2988 |
Molecular Targets for Tumor Radiosensitization
Tofilon PJ, Camphausen K |
| 2989 - 3011 |
ABC Efflux Pump-Based Resistance to Chemotherapy Drugs
Eckford PDW, Sharom FJ |
| 3012 - 3043 |
Impact of Natural Products on Developing New Anti-Cancer Agents
Cragg GM, Grothaus PG, Newman DJ |
| 3044 - 3079 |
The Halichondrins and E7389
Jackson KL, Henderson JA, Phillips AJ |
| 3080 - 3098 |
Variolins and Related Alkaloids
Walker SR, Carter EJ, Huff BC, Morris JC |
| 3099 - 3124 |
Molecular Regulation of Tumor Angiogenesis and Perfusion via Redox Signaling
Miller TW, Isenberg JS, Roberts DD |
| 3125 - 3140 |
Pharmacologic and Chemical Adjuvants in Tumor Virotherapy
Alvarez-Breckenridge C, Kaur B, Chiocca EA |
| 3141 - 3157 |
Dendrimers as Carriers for Delivery of Chemotherapeutic Agents
Medina SH, El-Sayed MEH |
| 3158 - 3199 |
Evidence for a Re-Evaluation of the Neurochemical and Anatomical Bases of Chemotherapy-Induced Vomiting
Darmani NA, Ray AP |
| 3200 - 3208 |
Cancer Stem Cells: A New Theory Regarding a Timeless Disease
Sarkar B, Dosch J, Simeone DM |
